id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-321698-8q25z6ci	Spratt, Daniel I	COVID-19 and Hypercoagulability: Potential Impact on Management with Oral Contraceptives, Estrogen Therapy and Pregnancy	2020-07-29		.txt	text/plain	825	58	41	title: COVID-19 and Hypercoagulability: Potential Impact on Management with Oral Contraceptives, Estrogen Therapy and Pregnancy Although all of the underlying mechanisms of COVID-associated hypercoagulability are not clear, multiple laboratory abnormalities related to coagulation occur commonly in hospitalized COVID-19 patients including increased levels of Ddimer, fibrinogen, fibrin, fibrinogen degradation products, and cytokines as well asdecreased antithrombin,variable platelet counts over the course of disease, and platelet-fibrin contraceptives (COC's) and other estrogen therapies as well as pregnancy-associated risks. As this Commentary is being submitted, no reports of increased incidence of VTEs in pregnant women or women taking estrogen preparations who also have COVID-19 have emerged. Establishing models for basic research into mechanisms of hypercoagulability in COVID-19, let alone intersecting effects of COVID-19 and estrogen therapy or pregnancy, has several hurdles and will require innovative novel animal and tissue models.	./cache/cord-321698-8q25z6ci.txt	./txt/cord-321698-8q25z6ci.txt